MS Pharma Partners with Formycon for Commercialization of FYB203 in MENA

Klinge Biopharma GmbH, holding global commercialization rights to FYB203, a biosimilar candidate to Eylea® (Aflibercept), has signed an exclusive licensing and supply agreement with MS Pharma for distribution in the Middle East and North Africa (MENA). This deal grants MS Pharma exclusive rights to commercialize and produce FYB203 locally, particularly at its new Biosimilars site in Saudi Arabia.

MS Pharma, a prominent name in the pharmaceutical sector within the MENA region, will undertake commercialization efforts leveraging its established infrastructure and market reach. The partnership also aims to foster local production, thereby improving healthcare access and boosting the regional economy. This collaboration extends the relationship between the companies, with MS Pharma already distributing Formycon's Lucentis® biosimilar, FYB201, in the region.

Formycon’s FYB203 is currently under regulatory review by the U.S. FDA and European Medicines Agency, with approvals anticipated in the coming years. FYB203 targets neovascular age-related macular degeneration and other serious retinal diseases by inhibiting VEGF, a key factor in abnormal blood vessel development in the retina.